Navigation Links
Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
Date:7/15/2008

ATHENS, Ga., July 15 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, announced today a strategic equity investment by Cato BioVentures and a collaboration with Cato Research Ltd., its global contract research and development organization. The investment and collaboration will help support continued development of Abeome's lead ovarian cancer project.

Abeome's proprietary technology vastly improves the development of monoclonal antibodies and Abeome is deploying its technology to provide a shotgun approach to develop an array of antibodies for an ovarian cancer therapeutic target. The company has developed novel monoclonal antibodies to four ovarian cancer cell lines and has begun screening these antibodies in search of those which cause either cancer cell growth inhibition or death.

Joel Eisner, Ph.D., Associate Principal of Cato BioVentures, states, "We are fascinated with Abeome's ability to develop such a large library of monoclonal antibodies by use of their technology. They have pushed the bottleneck of therapeutic development to the screening step which will provide a broader selection of novel antibodies to more cancer targets."

Monoclonal antibodies have become the centerpiece of many high-profile therapeutic products. Their specificity to disease targets, like cancer, has drawn significant attention from the biotech community.

"Ovarian cancer is a dreadful disease which is frequently diagnosed at a very late stage of development. With no effective therapeutic drugs on the market to date, we expect to address this unmet medical need. Our technology improves the likelihood of finding that one-of-a-kind antibody that can make the difference," said Mike Wanner, President and CEO of Abeome. "We are excited to have Cato Research join our expanding team of professional experts to help us with this important project".

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance.

For more information on Abeome, visit http://www.abeomecorp.com .

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of Cato Research Ltd. and has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital(TM) in innovative therapeutics, medical devices, diagnostics and platform technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park and Silicon Valley.

For more information on Cato BioVentures, visit http://www.catobioventures.com .


'/>"/>
SOURCE Abeome Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
2. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
3. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
4. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Pediatric Researchers Find Possible Master Switch Gene in Juvenile Arthritis
7. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
8. Small Business Innovation Research Program Awards Grant to Biomoda
9. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
10. New Research Just Released: Women Can Now Safely Postpone Motherhood Until Time Is Right
11. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):